Dhillon Punit

Chief Executive Officer, DirectorSkye Bioscience, Inc. (SKYE) · full profile →Form 4 · filed Apr 2, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
14
0 non-derivative · 14 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 31, 2026Grant(A)250K250K
Mar 31, 2026Disposed to issuer(D)250K0
Mar 31, 2026Grant(A)36K36K
Mar 31, 2026Disposed to issuer(D)36K0
Mar 31, 2026Grant(A)12K12K
Mar 31, 2026Disposed to issuer(D)12K0
Mar 31, 2026Grant(A)650K650K
Mar 31, 2026Disposed to issuer(D)650K0
Mar 31, 2026Grant(A)125K125K
Mar 31, 2026Disposed to issuer(D)125K0
Mar 31, 2026Grant(A)9K9K
Mar 31, 2026Disposed to issuer(D)9K0
Mar 31, 2026Grant(A)22K22K
Mar 31, 2026Disposed to issuer(D)22K0

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-023337) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.